Saturday 17 October 2026
Export CNTN’s income statement to Excel — free account
Canton Strategic Holdings, Inc.
CNTN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 85.9% and free cash flow fell 600.4%, each against the same quarter a year earlier.
1.70
0.17
−9.09%
Follow CNTN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
14.94 | — | — | — |
+8 more quarters Free account |
P/S ratio |
0.00 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(273.22) | — | — | — | |
P/B ratio |
1.34 | — | — | — | |
Price to Tangible BV |
0.00 | — | — | — | |
EV/Sales |
0.00 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(25.94) | — | — | — | |
EV/FCF |
(25.94) | — | — | — | |
Quick Ratio |
14.18 | 36.39 | 3.65 | 4.93 | |
Current Ratio |
15.70 | 37.75 | 5.29 | 4.98 | |
Net Debt/EBITDA |
30.98 | 1.13 | 0.86 | 3.62 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.45% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.01 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.12 | 0.16 | 0.35 | 0.88 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Interest Coverage |
— | — | (3,423.71) | (218.08) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
180.36% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.93 | 0.93 | 0.97 | 0.00 | |
Share Based Compensation of Revenue |
4.67% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.11) | — | — | — | |
Graham Number |
2.98 | — | — | — | |
Earnings Yield |
6.69% | — | — | — | |
Free Cash Flow Yield |
(3.63%) | — | — | — | |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.01) | (0.04) | (0.33) | (0.30) | |
Capex per Share |
(0.03) | (0.26) | (2.42) | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.30) | (2.75) | (0.30) | |
Cash per Share |
0.17 | 0.20 | 0.37 | 1.22 | |
Shareholders Equity per Share |
2.10 | 2.26 | 12.42 | 0.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.10 | 2.26 | 12.42 | 0.99 | |
Free Cash Flow |
(8.00) | (62.46) | (88.01) | (1.86) | |
Working Capital |
38.59 | 41.94 | 14.10 | 6.15 | |
Capital Expenditures |
(5.76) | (54.82) | (77.57) | — | |
Net Current Asset Value |
(68.45) | (71.77) | (103.83) | 6.15 | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
3.85 | 0.00 | 0.00 | — | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Payables |
0.84 | 0.62 | 0.81 | 0.72 | |
Average Assets |
283.55 | 293.16 | 261.43 | 6.48 | |
Average Common Equity |
227.64 | 234.49 | 199.62 | 4.59 |
Columns are period end dates